News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
683,249 Results
Type
Article (38964)
Company Profile (276)
Press Release (644009)
Section
Business (203819)
Career Advice (1985)
Deals (35357)
Drug Delivery (84)
Drug Development (80768)
Employer Resources (168)
FDA (16085)
Job Trends (14796)
News (344460)
Policy (32429)
Tag
Academia (2530)
Alliances (49035)
Alzheimer's disease (1215)
Approvals (16003)
Artificial intelligence (116)
Bankruptcy (352)
Best Places to Work (11465)
Biotechnology (196)
Breast cancer (107)
Cancer (898)
Cardiovascular disease (81)
Career advice (1656)
Cell therapy (198)
Clinical research (63917)
Collaboration (326)
Compensation (168)
COVID-19 (2522)
Cystic fibrosis (78)
Data (862)
Diabetes (133)
Diagnostics (6096)
Earnings (84140)
Employer resources (146)
Events (108843)
Executive appointments (246)
FDA (16528)
Funding (288)
Gene therapy (148)
GLP-1 (557)
Government (4317)
Healthcare (18652)
Infectious disease (2597)
Inflammatory bowel disease (102)
Interviews (308)
IPO (16268)
Job creations (3622)
Job search strategy (1415)
Layoffs (407)
Legal (7847)
Lung cancer (154)
Manufacturing (151)
Medical device (13147)
Medtech (13152)
Mergers & acquisitions (19108)
Metabolic disorders (360)
Neuroscience (1455)
NextGen Class of 2024 (6496)
Non-profit (4462)
Northern California (1205)
Obesity (214)
Opinion (176)
Patents (94)
People (56123)
Phase I (19820)
Phase II (28143)
Phase III (21014)
Pipeline (209)
Postmarket research (2553)
Preclinical (8429)
Radiopharmaceuticals (234)
Rare diseases (178)
Real estate (5888)
Regulatory (21438)
Research institute (2307)
Resumes & cover letters (349)
Southern California (1082)
Startups (3560)
United States (11622)
Vaccines (536)
Weight loss (159)
Date
Today (210)
Last 7 days (839)
Last 30 days (2858)
Last 365 days (35774)
2024 (30355)
2023 (40074)
2022 (51173)
2021 (55712)
2020 (54087)
2019 (46541)
2018 (35019)
2017 (32110)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (713)
Arizona (186)
Asia (37009)
Australia (6037)
California (2725)
Canada (1173)
China (209)
Colorado (117)
Connecticut (121)
Europe (79232)
Florida (392)
Georgia (98)
Illinois (306)
Indiana (177)
Kansas (95)
Maryland (515)
Massachusetts (2216)
Michigan (142)
Minnesota (250)
New Jersey (825)
New York (836)
North Carolina (662)
Northern California (1205)
Ohio (126)
Pennsylvania (745)
South America (1091)
Southern California (1082)
Texas (381)
Utah (79)
Washington State (321)
683,249 Results for "dermbiont inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Genetown
DermBiont Announces 2024 Development Pipeline Update for its First-in-Class Targeted Topical Therapeutics for Seborrheic Keratoses, Basal Cell Carcinomas, and Melasma
DermBiont announced updates on the company’s development pipeline, including the completion of enrollment in a Phase 2b clinical trial of SM-020 gel 1.0% for the treatment of SKs, and anticipated clinical milestones for 2024.
February 22, 2024
·
5 min read
Genetown
DermBiont Announces First Close of $35.2 Million in a Series B Financing to Advance First-in-Class Targeted Topical Dermatological Therapeutics
DermBiont, a clinical-stage biotechnology company that is advancing targeted topical therapeutics for the treatment of dermatological indications, today announced a $35.2 million Series B financing, including a $27.1 million Series B first close and $8.1 million in converting outstanding notes.
October 24, 2023
·
4 min read
Drug Development
DermBiont Announces Positive Data from a Phase 2 Trial Treating Solar Lentigos and Normalizing Pigmentation of the Skin with 0.8% SM-030 Topical Gel
DermBiont, a clinical-stage biotechnology company that is advancing targeted topical therapeutics for the treatment of dermatological indications, today announced positive data from its Phase 2 trial with 0.8% SM-030 gel, a product under development capable of regulating pigmentation by controlling the formation of new melanin.
May 30, 2023
·
6 min read
Drug Development
DermBiont Presents Positive Phase 2 Trial Data Treating Seborrheic Keratosis with SM-020 Topical Gel at American Academy of Dermatology Annual Meeting
DermBiont today announced that its Phase 2 adaptive design trial with of investigational drug SM-020 gel 1.0% met its primary endpoint of a one point improvement in Physician’s lesion assessment (PLA) score at last visit and safety via local tolerability, as well as key multiple secondary endpoints including complete clearance of treated lesions.
March 22, 2023
·
6 min read
Genetown
DermBiont Raises $28 Million and Acquires Chromaderm to Expand Targeted Topical Therapeutics in Development
DermBiont announced today that it has raised a $28 million Series A2 financing in parallel with the acquisition of clinical-stage biotechnology company Chromaderm.
December 21, 2021
·
4 min read
Drug Development
DermBiont Announces Positive Phase 2 Clinical Trial Data Treating Seborrheic Keratosis with SM-020, the First and Only Targeted Topical Treatment for these Common Benign Tumors
DermBiont, a clinical-stage biotechnology company announced today positive results meeting primary and secondary endpoints in a Phase 2 clinical trial with a topical formulation of investigational drug SM-020, a specific and potent AKT inhibitor applied by patients at home to their seborrheic keratoses (SK).
June 23, 2022
·
4 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Press Releases
Verrica Pharmaceuticals Announces Litigation Settlement with Dormer Laboratories, Inc.
Verrica Pharmaceuticals Inc. today announced the settlement of litigation with Dormer Laboratories, Inc. (“Dormer Labs”).
July 1, 2024
·
5 min read
Lophos Holdings Inc. Announces the Completion of Securities Purchase Agreement with ThreeD Capital Inc.
Lophos Holdings Inc. (CSE: MESC) (“Lophos” or the “Company”), a Canadian bioscience company focused on the cultivation and sale of Lophophora williamsii (“Peyote”) and ThreeD Capital Inc. (CSE: IDK) (OTCQB: IDKFF) (“ThreeD”), a Canadian-based venture capital firm focused on opportunistic investments in companies in the junior resources and disruptive technologies sectors, are pleased to announce the completion of its previously announced Securities Purchase Agreement (the “Agreement”).
June 20, 2024
·
4 min read
Press Releases
Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Announce Business Combination to Form Dogwood Therapeutics, Inc. (Nasdaq: “DWTX”)
October 8, 2024
·
14 min read
1 of 68,325
Next